Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new treatment.

BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...

Drugs already in use could be combined to form a two-pronged attack on advanced prostate cancer, a study suggests.

The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Alicia K. Morgans discussing ...

Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...

Men with genes that increase the risk of prostate cancer should have annual checks from the age of 40, research has shown.

My doctor was of the opinion that over-medicalisation of patients was a common problem, and that a high PSA reading might ...